Research programme: antibacterials - Novartis

Drug Profile

Research programme: antibacterials - Novartis

Alternative Names: CHIR 281; CHIR 380; CHIR 443; CHIR 530; CHIR 787; CHIR 988; EF-Tu inhibitors - Novartis; GE2270A; GINA-220; GINA-301; N'-p-octyloxybenzyl-L-alanyl-vancomycin; N'-p-octyloxybenzylglycyl-vancomycin; prokaryotic elongation factor Tu inhibitors - Novartis

Latest Information Update: 05 Apr 2011

Price : $50

At a glance

  • Originator Novartis
  • Class Heterocyclic acids; Ketolides
  • Mechanism of Action Peptide elongation factor Tu inhibitors; Protein synthesis inhibitors; Undecaprenyl pyrophosphate synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 31 Mar 2011 Preclinical development is ongoing in the US
  • 26 Mar 2009 This programme is still in active development
  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top